Categories AlphaGraphs, Earnings, Technology

VZ Earnings: Highlights of Verizon’s Q3 2022 financial results

Telecom giant Verizon Communications Inc. (NYSE: VZ)  on Friday reported a decline in net profit for the third quarter of 2022, despite an increase in revenues.

Verizon Q3 2022 earnings infographic

Third-quarter adjusted earnings declined to $1.32 per share from $1.42 per share in the comparable period of last year. Analysts were looking for a lower bottom line number. Unadjusted profit dropped to $5.02 billion or $1.17 per share from $6.55 billion or $1.55 per share last year.

Meanwhile, total operating revenues increased 4% annually to $34.24 billion during the three-month period, which was also above the consensus forecast.


Check this space to read management/analysts’ comments on Verizon’s Q3 2022 report


“The pricing actions we took earlier this year, as well as our new cost savings program, show that we are being deliberate and strategic in our decisions to strengthen our business. At the same time, we are focused on executing our 5G strategy, as we are covering every major market and accelerating our C-Band network build. We are on track to reach 200 million POPs within first-quarter 2023,” said Verizon’s CEO Hans Vestberg.

Prior Performance

  • Verizon Q1 2022 Earnings Infographic

_________________________________________________________________________________________________________________

Stocks you may like:

Apple (AAPL) Stock

Microsoft (MSFT) Stock

Alphabet (GOOGL) Stock

International Business Machines Corp. (IBM) Stock

_________________________________________________________________________________________________________________

Most Popular

Key takeaways from JM Smucker’s (SJM) Q4 2025 earnings report

Shares of The J.M. Smucker Co. (NYSE: SJM) plunged 15% on Tuesday after the company delivered mixed results for the fourth quarter of 2025. While earnings came ahead of expectations,

J.M. Smucker (SJM) Q4 2025 Earnings: Key financials and quarterly highlights

The J.M. Smucker Co. (NYSE: SJM) reported its fourth quarter 2025 earnings results today. Net sales was $2.1 billion, down 3% year-over-year. Comparable net sales decreased 1%. Net loss was

Plus Therapeutics CEO: Lead candidate REYOBIQ demonstrates strong safety and efficacy in early trials

Plus Therapeutics (NASDAQ: PSTV) is a pharmaceutical company engaged in the development of targeted radiotherapeutics for difficult-to-treat cancers. Currently, it is advancing a pipeline of product candidates with lead programs

Add Comment
Loading...
Cancel
Viewing Highlight
Loading...
Highlight
Close
Top